Medtronic. Dexcom. Abbott. Sanofi. Google. A lot of very large, well-known companies are investing heavily into innovating the diabetes space, and that innovation is exciting. But a disproportionate ...

Study design. This prospective, randomized, controlled, parallel-group study compared the use of pen devices with conventional vials and syringes for the administration of insulin in hospitalized ...

Biocon Ltd's biosimilar arm recently announced it will supply insulin glargine pens to US-based non-profit Civica.(istockphoto) Biocon Biologics Ltd is aiming to expand its insulin portfolio in the US ...